Pipeline-Prospector-Insert
X

Find drug development pipeline and deal Updates information

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Company Locations

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATI-450, Methotrexate

            Therapeutic Area: Immunology

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 09, 2020

            Details:

            ATI-450 resulted in inhibition of TNF?, IL1?, IL8, and IL6, was generally well-tolerated at all doses tested in the trial; had no significant food effect or drug-drug interaction with methotrexate.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): JSP191

            Therapeutic Area: Immunology

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Abingworth

            Deal Size: $50.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing January 09, 2020

            Details:

            Funds will be used to advance JSP191, the first clinical-stage antibody designed for use as a single and combination conditioning agent in patients undergoing curative allogeneic hematopoietic cell transplan